Today's Date: March 28, 2024
Equalpride Partners with TransLash Media for Trans Day of Visibility, Amplifying Voices of Black Trans Femmes in the Arts   •   Coachella Concerned That People Have Sex, Says AHF   •   YMCA of the USA Partners With Old Spice To Increase High School Graduation Among Boys And Young Men Of Color Through Mentorship   •   Amerex Group Unveils Red Carter Swimwear's Revitalized Collection   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   Jamieson Wellness Publishes Inaugural Sustainability Impact Report   •   Empire State Realty Trust Receives WELL Health-Safety Leadership Award; Becomes Among the First Commercial Office and Multifamil   •   National University Receives 2024 Military Friendly® Gold Designation   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS   •   John Legend to Perform at City Year Los Angeles’ 13th Annual Spring Break Event   •   Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages   •   Parkland Corporation Announces the Results of the 2024 Annual General Meeting of Shareholders   •   Fastenal Releases 2024 Environmental, Social, and Governance (ESG) Report   •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   Make-A-Wish and celebrity wish granters announce goal to recruit 1 million people to become "WishMakers"   •   Suffolk Kicks off 2024 “Build With Us @ Suffolk” Program in Boston for Trade Partners, Opening Doors for Minority-,   •   Carnegie Learning Named 2024 SIIA CODiE Award Finalist for Best Educational Game and Best AI Implementation in Ed Tech   •   Visit Visalia Recognizes Autism Awareness Month in April   •   Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™   •   Torrid Reports Fourth Quarter and Fiscal 2023 Results and Initiates Fiscal 2024 Guidance
Bookmark and Share

Zephyr AI Demonstrates Predictive Value of Artificial Intelligence (AI) with RWD for Label Expansion with Approved 3rd Generatio

TYSONS, Va. , June 02 /Businesswire/ - Zephyr AI, Inc. (“Zephyr AI”), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment to improve patients’ lives announced today a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

Tremendous progress has been achieved in recent years towards understanding the molecular underpinnings of cancer and has ushered in an era of precision medicine. Today, actionable biomarkers inform rational design of novel drugs, repurposing of existing medications, or new combination therapies. However, less than 20% of cancer patients are currently benefiting from these targeted therapies. There is therefore an acute need for new methods to identify the expanded population of patients who could benefit from existing drugs and improve patient selection and design of clinical trials evaluating new or repurposed drugs.

Zephyr AI’s machine learning algorithms identify pharmacological sensitivities and genetic vulnerabilities that fall outside the current single nucleotide variants or proteins that are typically used to identify patients that would respond to targeted therapies. Zephyr AI’s algorithms generate interpretable drug response predictions from real-world data (RWD) which are then validated with proven models.

Leveraging Zephyr AI’s Vulnerability NetworkTM Methodology, the poster will highlight the use of Zephyr AI’s systems biology informed machine learning framework, along with RWD from multiple tumor types, to identify the common genetic vulnerabilities in patients treated with an approved 3rd generation EGFR inhibitor. Using their Vulnerability NetworkTM Methodology, Zephyr AI was able to identify which patients would respond, even though they didn’t have the EGFR mutations listed in the drug’s label.

“Our goal is to enable more cancer patients to receive the benefits of precision medicine, especially those groups that are unrepresented in previous clinical trials,” said Zephyr AI CEO David L. Morgan II.

The company believes that their machine learning technology could be used in the future for drug target discovery, preclinical experiment optimization, candidate selection, patient enrollment, and post market label updates. Zephyr AI will partner with pharmaceutical companies and clinicians to use its advanced analytics to clean and interpret their existing data as well as layer in additional RWD and evidence.

About Zephyr AI

Zephyr AI is a high-growth healthcare technology company committed to radically reshaping traditional approaches to precision medicine. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer, diabetes, and other diseases. Visit us at www.zephyrai.bio and follow us on Twitter, Instagram and LinkedIn.


STORY TAGS: Conference, Product/Service, Virginia, Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Software, Artificial Intelligence, Internet, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News